Summary
GlobalData, the industry analysis specialist's new report, "Anti-Hypertension-Drug Pipeline Analysis and Market Forecasts to 2016" is an essential source of information and analysis on the global anti-hypertension market, a key segment within the pharmaceutical and healthcare industry. This pharma report identifies the key trends shaping and driving the global anti-hypertension market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global anti-hypertension sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData's team of industry experts.

Scope
The scope of the report includes:
-Annualized global anti-hypertension market revenues data from 2001 to 2009, forecast forward for seven years to 2016.
-Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France and Japan.
-Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The first-in-class drugs act through new mechanisms of action such as eNOS (Endothelial Nitric Oxide Synthase) couplers, sodium-glucose transport 2 (SGLT2) inhibitors, endothelin antagonists, peroxisome proliferator-activated receptor (PPAR)-gamma agonists and cyclooxygenase-1 (COX-1) inhibitors.
-Analysis of the current and future market competition in the global anti-hypertension market. Key future market-players covered are Novartis Ag, Merck & Co. Inc., AstraZeneca, Takeda Pharmaceuticals, Daiichi Sankyo Co. Ltd, GlaxoSmithKline Plc, and Sanofi-Aventis. 
-Insightful reviews of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
-Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the future market associated with anti-hypertension.

Reasons to buy
The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
-Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
-Develop business strategies by understanding the trends shaping and driving the global anti-hypertension market.
-Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global anti-hypertension market in future.
-Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
-Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
-Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
-What's the next big thing in the global anti-hypertension market landscape? -Identify, understand and capitalize.

Table of Contents
1 Table of contents
1 Table of contents 3
1.1 List of Tables 5
1.2 List of Figures 5
2 Anti-hypertension Market: Market Characterization 6
2.1 Overview 6
2.2 Anti-hypertension Market Size 6
2.3 Anti-hypertension Market Forecast and CAGR 7
2.4 Drivers and Barriers for Anti-hypertension Market 8
2.4.1 Drivers for Anti-hypertension Market 8
2.4.2 Restraints for Anti-hypertension Market 8
2.5 Opportunity and Unmet Need 9
2.5.1 Unmet Needs 9
2.5.2 Impact Analysis of Unmet Needs 9
2.6 Key Takeaway 10
3 Anti-hypertension Market: Competitive Assessment 11
3.1 Overview 11
3.2 Strategic Competitor Assessment 11
3.3 Product Profile for the Major Marketed Products in the Anti-hypertension Market 12
3.3.1 Angiotensin II Receptor Blockers (ARBs) 12
3.3.2 Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors) 16
3.3.3 Diuretics 18
3.3.4 Beta Blockers 20
3.3.5 Calcium Channel Blockers 23
3.4 Key Takeaway 25
4 Anti-hypertension Market: Pipeline Assessment 28
4.1 Overview 28
4.2 Strategic Pipeline Assessment 28
4.2.1 Technology Trends Analytic Framework 28
4.3 Hypertension-Promising Drugs under Clinical Development 30
4.4 Molecule Profile for Promising Drugs under Clinical Development 31
4.4.1 SPP635 31
4.4.2 Pioglitazone 32
4.5 Anti-hypertension Market-Clinical Pipeline by Mechanism of Action 33
4.6 Hypertension Pipeline-Pipeline by Clinical Phases of Development 34
4.6.1 Hypertension-Regulatory Filing and Phase III Clinical Pipeline 34
4.6.2 Hypertension-Phase II Clinical Pipeline 37
4.6.3 Hypertension-Phase I Clinical Pipeline 39
4.6.4 Hypertension-Preclinical Pipeline 41
4.6.5 Hypertension-Discovery Pipeline 42
4.7 Discontinued/Suspended Drugs for Hypertension 42
4.8 Key Takeaway 42
5 Anti-hypertension Market: Implications for Future Market Competition 43
6 Anti-hypertension Market: Future Players in Anti-hypertension Market 45
6.1 Introduction 45
6.2 Novartis AG 45
6.2.1 Company Overview 45
6.2.2 Business Description 46
6.2.3 Hypertension Portfolio 46
6.3 Merck & Co. Inc. 47
6.3.1 Overview 47
6.3.2 Business Description 48
6.3.3 Hypertension Portfolio 48
6.4 AstraZeneca 49
6.4.1 Overview 49
6.4.2 Business Description 50
6.4.3 Hypertension Portfolio 51
6.5 Daiichi Sankyo Co.Ltd 51
6.5.1 Company Overview 51
6.5.2 Business Description 52
6.5.3 Hypertension Portfolio 52
6.6 Boehringer Ingelheim GmbH 53
6.6.1 Company Overview 53
6.6.2 Business Description 53
6.6.3 Hypertension Portfolio 54
6.7 GlaxoSmithKline 54
6.7.1 Company Overview 54
6.7.2 Business Description 55
6.7.3 Hypertension Portfolio 55
6.8 Sanofi-aventis 55
6.8.1 Company Overview 55
6.8.2 Business Description 56
6.8.3 Hypertension Portfolio 56
7 Anti-hypertension Market: Appendix 58
7.1 Definitions 58
7.2 Acronyms 58
7.3 Research Methodology 59
7.3.1 Coverage 59
7.3.2 Secondary Research 60
7.3.3 Forecasting 60
7.3.4 Primary Research 62
7.3.5 Expert Panel validation 63
7.4 Contact Us 63
7.5 Disclaimer 63
7.6 Sources 63

List of Tables
1.1 List of Tables
Table 1: Anti-hypertension Market, Global, Sales Value ($ bn), 2001-2009 7
Table 2: Anti-hypertension Market, Global, Sales Value ($ bn), 2009-2016 7
Table 3: Anti-hypertension Market, Global, Diovan, Adverse Reactions 14
Table 4: Anti-hypertension Market, Global, Cozaar, Adverse Reactions 15
Table 5: Anti-hypertension Market, Global, Vasotec, Adverse Reactions 17
Table 6: Anti-hypertension Market, Global, Lotensin, Adverse Reactions 18
Table 7: Anti-hypertension Market, Global, Thiazide Diuretics, Adverse Reactions 19
Table 8: Anti-hypertension Market, Global, Loop Diuretics, Adverse Reactions 20
Table 9: Anti-hypertension Market, Global, Toprol-XL, Adverse Reactions 21
Table 10: Anti-hypertension Market, Global, Tenormin, Adverse Reactions 22
Table 11: Anti-hypertension Market, Global, Norvasc, Adverse Reactions 24
Table 12: Anti-hypertension Market, Global, Plendil, Adverse Reactions 25
Table 13: Anti-hypertension Market, Global, Marketed Products Comparison, 2010 25
Table 14: Anti-hypertension Market, Global, Most Promising Drugs Under Clinical Development, 2010 30
Table 15: Anti-hypertension Market, Global, Regulatory and Phase III Pipeline, 2010 34
Table 16: Anti-hypertension Market, Global, Phase II Pipeline, 2010 37
Table 17: Anti-hypertension Market, Global, Phase I Pipeline, 2010 39
Table 18: Anti-hypertension Market, Global, Preclinical Pipeline, 2010 41
Table 19: Anti-hypertension Market, Global, Discovery Stage Pipeline, 2010 42
Table 20: Anti-hypertension Market, Global, Terminated Pipeline Drugs, 2010 42
Table 21: Anti-hypertension Market, Global, Novartis Marketed Products, 2010 46
Table 22: Anti-hypertension Market, Global, Novartis Pipeline Drugs, 2010 47
Table 23: Anti-hypertension Market, Global, Merck & Co. Marketed Products, 2010 48
Table 24: Anti-hypertension Market, Global, Merck & Co. Pipeline Drugs, 2010 49
Table 25: Anti-hypertension Market, Global, AstraZeneca Marketed Products, 2010 51
Table 26: Anti-hypertension Market, Global, AstraZeneca Pipeline Drugs, 2010 51
Table 27: Anti-hypertension Market, Global, Daiichi Sankyo Marketed Products, 2010 52
Table 28: Anti-hypertension Market, Global, Daiichi Sankyo Pipeline Drugs, 2010 53
Table 29: Anti-hypertension Market, Global, Boehringer Ingelheim Marketed Products, 2010 54
Table 30: Anti-hypertension Market, Global, Boehringer Ingelheim Pipeline Drugs, 2010 54
Table 31: Anti-hypertension Market, Global, GlaxoSmithKline Marketed Products, 2010 55
Table 32: Anti-hypertension Market, Global, GlaxoSmithKline Pipeline Drugs, 2010 55
Table 33: Anti-hypertension Market, Global, Sanofi-Aventis Marketed Products, 2010 56
Table 34: Anti-hypertension Market, Global, sanofi-aventis Pipeline Drugs, 2010 57

List of Figures
1.2 List of Figures
Figure 1:  Anti-hypertension Market, Global, Sales Value ($ bn), 2001-2016 7
Figure 2:  Anti-hypertension Market, Global, Market Opportunity and Unmet Needs, 2010 10
Figure 3:  Anti-hypertension Market, Global, Strategic Competitor Assessment of Major Marketed Products, 2010 12
Figure 4:  Anti-hypertension Market, Global, Pipeline, Technology Trends Analytic Framework, 2010 29
Figure 5:  Anti-hypertension Market, Global, Pipeline, Description of Technology Trends Analytic Framework, 2010 30
Figure 6:  Anti-hypertension Market-Clinical Pipeline by Mechanism of Action, 2010 33
Figure 7:  Anti-hypertension Market, Global, Pipeline by Phase of Clinical Development, 2010 34
Figure 8:  Anti-hypertension Market, Global, Implications for Future Market Competition in the Anti-hypertension Market, 2010 43
Figure 9:  Anti-hypertension Market, Global, Clinical Pipeline by Company, 2010 45
Figure 10:  GlobalData Methodology 59
Figure 11:  GlobalData Market Forecasting Model 62